Submit the NDA for relacorilant
Delivered after the deadline (549 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 8 Feb 2021
- Due
- 30 Jun 2023
- Delivered
- 30 Dec 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The delay may be as long as one year, to the second quarter of 2023.”
What we found
Evidence strength A What the grades mean
The company committed to submitting the NDA in Q1 2024 but did not submit it until December 30, 2024.
-
A Corcept Therapeutics Inc. 8-K filed 2024-05-01
“Relacorilant New Drug Application (NDA) – NDA submission for Cushing’s syndrome expected this quarter” ✓ confirmed on the page
-
A Corcept Therapeutics Inc. 10-K filed 2025-02-26
“On December 30, 2024, we submitted to the United States Food and Drug Administration (“FDA”) a New Drug Application (“NDA”) for a proprietary cortisol modulator we have developed, relacorilant” ✓ confirmed on the page
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 1 versions
-
Version 1 · original · stated 8 Feb 2021
Deadline 30 Jun 2023 (“second quarter of 2023”)
-
Version 2 · stated 28 Feb 2023
Deadline 31 Mar 2024 (“first quarter of 2024”) · wording expected
“new drug application (NDA) submission expected in the first quarter of 2024”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- NDA submission for relacorilant
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: duration and severity of pandemic-related restrictions
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Corcept Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CORT-023295 · Corrections policy